|
'''Programmed cell death 1 ligand 2''' (also known as PD-L2, B7-DC) is a [[protein]] that in humans is encoded by the ''PDCD1LG2'' [[gene]].[{{cite journal | vauthors = Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ | title = PD-L2 is a second ligand for PD-1 and inhibits T cell activation | journal = Nature Immunology | volume = 2 | issue = 3 | pages = 261–268 | date = March 2001 | pmid = 11224527 | doi = 10.1038/85330 | s2cid = 27659586 }}][{{cite web | title = Entrez Gene: PDCD1LG2 programmed cell death 1 ligand 2 | url = https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=80380 }}] PDCD1LG2 has also been designated as '''CD273''' ([[cluster of differentiation]] 273). PDCD1LG2 is an [[immune checkpoint]] receptor ligand which plays a role in negative regulation of the [[Adaptive immune system|adaptive immune]] response.[{{cite journal | vauthors = McDermott DF, Atkins MB | title = PD-1 as a potential target in cancer therapy | journal = Cancer Medicine | volume = 2 | issue = 5 | pages = 662–673 | date = October 2013 | pmid = 24403232 | pmc = 3892798 | doi = 10.1002/cam4.106 }}] PD-L2 is one of two known ligands for [[Programmed cell death protein 1]] (PD-1),[{{cite journal | vauthors = Philips EA, Garcia-España A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP | title = The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals | journal = The Journal of Biological Chemistry | volume = 295 | issue = 14 | pages = 4372–4380 | date = April 2020 | pmid = 31882544 | doi = 10.1074/jbc.AC119.011747 | pmc = 7135984 | doi-access = free }}][{{cite journal | vauthors = Hu CB, Huang C, Wang J, Hong Y, Fan DD, Chen Y, Lin AF, Xiang LX, Shao JZ | title = PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish | journal = Journal of Immunology | volume = 211 | issue = 5 | pages = 816–835 | date = September 2023 | pmid = 37486225 | doi = 10.4049/jimmunol.2300217 }}][{{cite journal | vauthors = Kondo R, Kondo K, Nabeshima K, Nishikimi A, Ishida Y, Shigeoka T, Dijkstra JM | title = PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution | journal = Frontiers in Immunology | volume = 16 | article-number = 1573492 | date = 2025-05-28 | pmid = 40503235 | pmc = 12151841 | doi = 10.3389/fimmu.2025.1573492 | doi-access = free }}] |
|
'''Programmed cell death 1 ligand 2''' (also known as PD-L2, B7-DC) is a [[protein]] that in humans is encoded by the ''PDCD1LG2'' [[gene]].[{{cite journal | vauthors = Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ | title = PD-L2 is a second ligand for PD-1 and inhibits T cell activation | journal = Nature Immunology | volume = 2 | issue = 3 | pages = 261–268 | date = March 2001 | pmid = 11224527 | doi = 10.1038/85330 | s2cid = 27659586 }}][{{cite web | title = Entrez Gene: PDCD1LG2 programmed cell death 1 ligand 2 | url = https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=80380 }}] PDCD1LG2 has also been designated as '''CD273''' ([[cluster of differentiation]] 273). PDCD1LG2 is an [[immune checkpoint]] receptor ligand which plays a role in negative regulation of the [[Adaptive immune system|adaptive immune]] response.[{{cite journal | vauthors = McDermott DF, Atkins MB | title = PD-1 as a potential target in cancer therapy | journal = Cancer Medicine | volume = 2 | issue = 5 | pages = 662–673 | date = October 2013 | pmid = 24403232 | pmc = 3892798 | doi = 10.1002/cam4.106 }}] PD-L2 is one of two known ligands for [[Programmed cell death protein 1]] (PD-1),[{{cite journal | vauthors = Philips EA, Garcia-España A, Tocheva AS, Ahearn IM, Adam KR, Pan R, Mor A, Kong XP | title = The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals | journal = The Journal of Biological Chemistry | volume = 295 | issue = 14 | pages = 4372–4380 | date = April 2020 | pmid = 31882544 | doi = 10.1074/jbc.AC119.011747 | pmc = 7135984 | doi-access = free }}][{{cite journal | vauthors = Hu CB, Huang C, Wang J, Hong Y, Fan DD, Chen Y, Lin AF, Xiang LX, Shao JZ | title = PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell-Initiated Adaptive Immunity in Zebrafish | journal = Journal of Immunology | volume = 211 | issue = 5 | pages = 816–835 | date = September 2023 | pmid = 37486225 | doi = 10.4049/jimmunol.2300217 }}][{{cite journal | vauthors = Kondo R, Kondo K, Nabeshima K, Nishikimi A, Ishida Y, Shigeoka T, Dijkstra JM | title = PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution | journal = Frontiers in Immunology | volume = 16 | article-number = 1573492 | date = 2025-05-28 | pmid = 40503235 | pmc = 12151841 | doi = 10.3389/fimmu.2025.1573492 | doi-access = free }}] |
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
